Literature DB >> 18084326

The EWS/FLI1 oncogenic transcription factor deregulates GLI1.

J P Zwerner1, J Joo, K L Warner, L Christensen, S Hu-Lieskovan, T J Triche, W A May.   

Abstract

Ewing family tumors (EFT), classically Ewing's sarcoma and peripheral primitive neuroectodermal tumor, share a common class of tumor-specific fusion genes thought to be key mediators of tumor biology. Here we demonstrate that the most common Ewing's fusion, EWS/FLI1, produces transcriptional upregulation of GLI1 and its direct transcriptional target PATCHED1 in a model transformation system. This deregulation of GLI1 is common to other EWS/ets chimera and depends on the functional transcriptional regulatory domains. Inhibition of GLI1 via RNAi or via overexpression of endogenous inhibitors results in a reduction of EWS/FLI1 transformation activity. Activation of GLI1 appears to occur in a Hedgehog-independent fashion as blockade of Hedgehog signaling has only a modest effect on EFT cells. We present evidence that EWS/FLI1 upregulation of cMYC may play a role in the upregulation of GLI1 in EWS/FLI1-transformed NIH3T3 cells. Finally, we demonstrate that observations made in a model transformation system translate to an Ewing cellular background. EFT cell lines express GLI1 and PATCHED and this expression is EWS/FLI1 dependent. Inhibition of GLI1 expression via RNAi results in reduced anchorage-independent growth in an EFT cell line. GLI1 appears to be a transcriptionally deregulated target of EWS/FLI1 that mediates a portion of its tumorigenic phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084326     DOI: 10.1038/sj.onc.1210991

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  72 in total

Review 1.  Targeting Hedgehog--a cancer stem cell pathway.

Authors:  Akil A Merchant; William Matsui
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 3.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

4.  Arsenic: a potentially useful poison for Hedgehog-driven cancers.

Authors:  G Praveen Raju
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Authors:  Elspeth M Beauchamp; Lymor Ringer; Gülay Bulut; Kamal P Sajwan; Michael D Hall; Yi-Chien Lee; Daniel Peaceman; Metin Ozdemirli; Olga Rodriguez; Tobey J Macdonald; Chris Albanese; Jeffrey A Toretsky; Aykut Uren
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 6.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

Review 7.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

8.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 9.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

Authors:  Elspeth Beauchamp; Gulay Bulut; Ogan Abaan; Kevin Chen; Akil Merchant; William Matsui; Yoshimi Endo; Jeffrey S Rubin; Jeffrey Toretsky; Aykut Uren
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.